周三，H.C. Wainwright更新了对Opus Genetics (NASDAQ:IRD)股票的评级，给予"买入"评级，目标价为$8.00。该公司分析师指出了公司遗传性视网膜疾病 (IRD)平台的潜力，该平台包括针对Leber先天性黑矇 (LCA)、Best黄斑营养不良 (BEST1)和视网膜色素变性 (RP)的治疗方案。

根据AI大模型测算威孚高科后市走势。短期趋势看，该股当前无连续增减仓现象，主力趋势不明显。主力没有控盘。中期趋势方面，下方累积一定获利筹码。近期该股获筹码青睐，且集中度渐增。舆情分析来看，1家机构预测目标均价21.00，高于当前价15.77%。目前市场情绪悲观。

IRD在今年6月发布的绩效改进报告中表示，税务局将致力于评估并报告估算的成本和收益，并报告"税收缺口"--税收缺口指纳税人或企业在应该纳税时却未纳税的情况。

Fi, LAN and internet connectivity to service its 20 nationwide sites and 4,100 staff in a deal that could last up to a decade ...

"Since we became aware of IRD using taxpayer information to run targeted social media campaigns, New Zealanders have been ...

Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to earnings of $0.25 per share a year ago. These ...

根据AI大模型测算威孚高科后市走势。短期趋势看，该股当前无连续增减仓现象，主力趋势不明显。主力没有控盘。中期趋势方面，下方累积一定获利筹码。近期筹码减仓，但减仓程度减缓。舆情分析来看，1家机构预测目标均价21.00，高于当前价18.38%。目前市场情绪中性。

“Rather than saying IRD is ending the leaks because it was wrong to leak data, he’s blamed the Taxpayers’ Union’s campaign ...

英为财情Investing.com - Opus Genetics (NASDAQ: IRD)星期二发布了第三季度的财报，数据显示，公司营收高于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.290，总营收为$3.87M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$2.28M，每股收益为$-0.253. 财报公布后 ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research ...

The IRD Duhallow Business Awards, now one of the most prestigious events in the North Cork Calendar, took place at the James ...

Significant funding has been announced for Social Farming in Ireland with various national projects to benefit including IRD ...